Clinical trials: Metabolism
Sleep Apnea, Obstructive, Diabetes Mellitus, Type 2
Obstructive Sleep Apnea (OSA), Sleepiness, and Activity in Diabetes Management
Daily physical activity is important to achieve glucose control in persons with type 2 diabetes. The purpose of this study is to explore if obstructive sleep apnea and its daytime symptom, excessive sleepiness, act as barriers to…
- Trial name
- OSA_DM (NCT00801892)
- Testing
- Continuous Positive Airway Pressure (CPAP)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Eileen R. Chasens
Diabetes Mellitus, Type 2
Delish Study: Diabetes Education to Lower Insulin, Sugars, and Hunger
Type 2 diabetes mellitus (T2DM) is the most expensive chronic disease in the U.S. Lifestyle modification is central to T2DM management, but long-term adherence to dietary recommendations is difficult.
- Trial name
- Delish (NCT03207711)
- Testing
- Carbohydrate-restricted diet, Mindfulness
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of California, San Francisco
Obesity
Harmonic Versus Electro Surgery in Lower Body Lift Procedures
The objective of this study is to determine if the use of The Harmonic™ (an ultrasonic surgical instrument) in Lower Body Lift procedures reduces volume and duration of wound drainage after surgery when compared to Electro…
- Trial name
- LBL (NCT00522171)
- Testing
- The Harmonic™ ultrasonic scalpel
- Where
- 2 sites in United States, Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Ethicon Endo-Surgery
Type 1 Diabetes
Novel mHealth Physical Activity Intervention for Youth With Type 1 Diabetes Mellitus
The goal of this longitudinal cohort study is to learn about a mHealth intervention in Type 1 Diabetes (T1D) The main question[s] it aims to answer are: Does the intervention increase the amount of text messages between the…
- Trial name
- NCT06018844
- Testing
- NUDGE
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Children's Mercy Hospital Kansas City
Obesity
Visual Feedback Monitoring During Exercise in Individuals With Obesity
Exercise has been shown to offer numerous health benefits and be particularly important in preventing weight gain or regain for people with obesity.
- Trial name
- NCT04685707
- Testing
- Visual feedback monitoring system (HFFS), Control
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Mississippi Medical Center
Type 2 Diabetes
A Local Experiential Study With Sitagliptin (an Antihyperglycemic Drug) in 30 Patients With Type 2 Diabetes Mellitus (0431-178)
This study will assess, over a 4-week treatment period, the safety and efficacy of the addition of sitagliptin to metformin in participants with type 2 diabetes mellitus (T2DM) who failed to achieve glycemic control on metformin…
- Trial name
- NCT01034111
- Testing
- Sitagliptin phosphate, Metformin
- Volunteers
- 30 people
- Sponsor
- Merck Sharp & Dohme LLC
Pompe Disease
First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221
This is an international, multi-center, open-label study designed to evaluate if the co-administration of investigational new drugs ATB200 and AT2221 is safe in adults with Pompe disease.
- Trial name
- NCT02675465
- Testing
- ATB200, AT2221
- Where
- 19 sites in United States, Australia and 4 more
- Volunteers
- 29 people
- Sponsor
- Amicus Therapeutics
Type 2 Diabetes
Safety and Efficacy Study to Compare Vildagliptin to Pioglitazone as Adding on Metformin in Type 2 Diabetes
The purpose of this study is to compare the effect of 16 weeks treatment with vildagliptin to pioglitazone as add-on the therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
- Trial name
- NCT01882907
- Testing
- vildagliptin, Pioglitazone
- Where
- 15 sites in South Korea
- Volunteers
- 287 people
- Sponsor
- Pusan National University Hospital
Hypertension, Diabetes
Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes
The purpose of this study was to evaluate the antihypertensive and antiglycemic effects, as well as the safety and tolerability of TAK-491 (azilsartan medoxomil), once daily (QD), in stage 1 hypertensive, type 2 diabetes mellitus…
- Trial name
- NCT01496430
- Testing
- Azilsartan medoxomil
- Where
- 68 sites in United States
- Volunteers
- 105 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Closed Loop Glucose Control in Patients With Type 1 and Type 2 Diabetes
This is a proof of concept safety study of an artificial intelligence based closed loop glucose control system designed for use in the intensive care unit setting.
- Trial name
- NCT05644730
- Testing
- Fusion closed loop glucose control system
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Ideal Medical Technologies
Frontotemporal Dementia, Right Sided Cerebral Hemisphere Cerebrovascular Accident
Efficacy of Web-Based Social-Cognitive Interventions in Right Hemisphere Stroke and Frontotemporal Dementia
This study is being done to test the feasibility and effectiveness of web-based social-cognitive training exercises in treating social-emotional deficits in patients with stroke or frontotemporal dementia (FTD).
- Trial name
- NCT02506036
- Testing
- Brain HQ
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Johns Hopkins University
Psoriasis, Cardiovascular Disease
Vascular Inflammation in Psoriasis - Extension Study
VIP-E is a one-arm, open-label, 40-52 week extension study to continue or cross over subjects of the VIP study (# 814278) to active drug (adalimumab) to determine if there is sustained improvement in vascular inflammation, lipid…
- Trial name
- VIP-E (NCT01866592)
- Testing
- Adalimumab
- Where
- 9 sites in United States
- Volunteers
- 81 people
- Sponsor
- University of Pennsylvania
NASH - Nonalcoholic Steatohepatitis
Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)
This is a randomized, double-blind, placebo-controlled study that will evaluate the safety, efficacy, tolerability of BIO89-100 in patients with biopsy-confirmed fibrosis stages F2-F3 NASH.
- Trial name
- ENLIVEN (NCT04929483)
- Testing
- BIO89-100
- Where
- 89 sites in United States, Puerto Rico
- Volunteers
- 222 people
- Sponsor
- 89bio, Inc.
HIV Infections, Hepatic Steatosis
Pioglitazone to Treat Fatty Liver in People With HIV Infection
This study will determine whether pioglitazone (Actos, a drug approved to treat diabetes, can benefit HIV-infected people with fatty liver.
- Conditions
- HIV Infections, Hepatic Steatosis, Insulin Resistance
- Trial name
- NCT00441272
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Obesity
Study of Obese Subjects Previously Implanted With the EndoBarrier Gastrointestinal Liner
The purpose of this study is to determine whether the GI Endobarrier Liner can be reimplanted.
- Trial name
- NCT01372501
- Testing
- Endobarrier Liner
- Where
- Chile
- Volunteers
- 19 people
- Sponsor
- Morphic Medical Inc.
Type 2 Diabetes Treated With Insulin
Control-IQ Technology in Individuals With Type 2 Diabetes
A prospective, multicenter study of 6 weeks of home use of Control-IQ technology in individuals with type 2 diabetes age 18 and older.
- Trial name
- 2IQ (NCT05111301)
- Testing
- Control-IQ technology 1.5
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Tandem Diabetes Care, Inc.
Diabetes Mellitus, Chronic Obstructive Pulmonary Disease
A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD
A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics with Chronic Obstructive Pulmonary Disease.
- Trial name
- NCT00138671
- Testing
- Subcutaneous Insulin, Inhaled Insulin
- Where
- 88 sites in United States, Brazil and 3 more
- Volunteers
- 105 people
- Sponsor
- Pfizer
Healthy Volunteers, Hepatic Insufficiency
A Single Dose Study of LY2605541 in Participants With Liver Impairment
The primary purpose of this study is to help answer the following research questions: To evaluate how much of the study drug (LY2605541) is in the blood of participants with varying degrees of liver impairment compared to those…
- Conditions
- Healthy Volunteers, Hepatic Insufficiency, Diabetes Mellitus, Type 2
- Trial name
- NCT01751399
- Testing
- LY2605541
- Where
- 2 sites in Germany, Hungary
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes
The primary research question is to evaluate whether, among patients with type 2 diabetes mellitus (T2D), initiation of empagliflozin changes the adjusted incidence of outcomes compared with initiation of Glucagon-Like Peptide-1…
- Trial name
- NCT03993132
- Testing
- Empagliflozin, Liraglutide
- Where
- Denmark
- Volunteers
- 26,774 people
- Sponsor
- Boehringer Ingelheim
Diabetic Macular Edema
Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab
This is an open-label, Phase I/II study of intravitreally administered ranibizumab either 0.5-mg and/or 2.0-mg in subjects with clinical, angiographic, and ocular coherence tomography (OCT) evidence of diabetic retinopathy with…
- Trial name
- REEF (NCT01292798)
- Testing
- Ranibizumab
- Where
- 5 sites in United States
- Volunteers
- 43 people
- Sponsor
- California Retina Consultants
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.